Literature DB >> 9773395

A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution.

A Yafune1, M Takebe, H Ogata.   

Abstract

This paper describes a use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution. In the proposed approach, a multivariate lognormal distribution is assumed for a population distribution of pharmacokinetic (PK) parameters. The maximum likelihood method is employed to estimate the population means, variances, and correlation coefficients of the multivariate lognormal distribution. Instead of a first-order Taylor series approximation to a nonlinear PK model, the proposed approach employs a Monte Carlo integration for the multiple integral in maximizing the log likelihood function. Observations below the lower limit of detection, which are usually included in Phase 1 PK data, are also incorporated into the analysis. Applications are given to a simulated data set and an actual Phase 1 trial to show how the proposed approach works in practice.

Mesh:

Year:  1998        PMID: 9773395     DOI: 10.1023/a:1023280909207

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

4.  Mixed-effects nonlinear regression for unbalanced repeated measures.

Authors:  E F Vonesh; R L Carter
Journal:  Biometrics       Date:  1992-03       Impact factor: 2.571

5.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

6.  Population pharmacokinetic modeling: the importance of informative graphics.

Authors:  E I Ette; T M Ludden
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

7.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

8.  An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

Authors:  J Wakefield; A Racine-Poon
Journal:  Stat Med       Date:  1995 May 15-30       Impact factor: 2.373

9.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

10.  A Bayesian approach to nonlinear random effects models.

Authors:  A Racine-Poon
Journal:  Biometrics       Date:  1985-12       Impact factor: 2.571

View more
  1 in total

1.  A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics.

Authors:  Tze Leung Lai; Mei-Chiung Shih; Samuel P Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-10       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.